Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
Hyperglycemic impairment is counteracted by benfotiamine
October 5th, 2006
Hyperglycemic impairment is counteracted by benfotiamine. "Dysfunction of mature endothelial cells is thought to play a major role in both micro- and macrovascular complications of diabetes. However, recent advances in biology of endothelial progenitor cells (EPCs) have highlighted their involvement in diabetes complications," scientists writing in the journal Diabetes report. "To determine the effect of glucotoxicity on EPCs, human EPCs have been isolated from peripheral blood mononuclear cells of healthy donors and cultured in the presence or absence of high glucose (33 mmol/L) or high glucose plus benfotiamine to scavenge glucotoxicity,"...
Source: Blood Weekly (2006-10-05)
|
